期刊文献+

度洛西汀治疗老年糖尿病患者周围神经痛的疗效观察 被引量:2

Clinical effect of duloxetine on elderly patients with diabetes peripheral neuropathic pain
原文传递
导出
摘要 目的探讨分析度洛西汀治疗糖尿病周围神经痛的临床疗效。方法将2012年4月至2014年5月平顶山市第一人民医院收治的74例糖尿病周围神经痛患者随机分为两组,治疗组37例应用度洛西汀治疗,对照组37例应用阿米替林治疗。治疗后,比较两组疗效和不良反应,并观察两组治疗前后的VAS评分变化。结果治疗后,治疗组总有效率为89.19%,高于对照组的70.27%,差异有统计学意义(P〈0.05);两组各个时间点的VAS评分均明显低于治疗前(P〈0.05),但治疗组治疗1、2、4周的VAS评分均明显低于对照组,其不良反应发生率也低于对照组,差异均有统计学意义(P〈0.05)。结论度洛西汀治疗糖尿病周围神经痛的临床疗效显著,具有临床推广价值。 Objective To investigate the clinical efficacy of duloxetine on elderly patients with diabetes peripheral neuropathic pain. Methods Seventy-four patients with diabetes peripheral neuro- pathic pain in the first people' s hospital of Pingdingshan from April 2012 to May 2014 were divided into two groups: the treatment group (n = 37) was treated by duloxetine and the control group (n = 37 ) was treated by amitriptyline treatment. After treatment, the curative effect, adverse reactions and VAS score in the two groups were observed. Results After treatment, the total effective rate of the treatment group( 89. 19% ) was significantly higher than that of the control group (70.27% , P 〈 0.05 ) ; All time points of VAS scores of two groups were significantly lower than before treatment ( P 〈 0.05 ). After treatment for 1, 2 and 4 weeks, the VAS scores of treatment group were significantly lower than that in the control group, the incidence of adverse reactions was lower than the control group ( P 〈 0.05 ). Conclusions The clinical efficacy of duloxetine on elderly patients with diabetes peripheral neuropathic pain is significant and has clinical value.
出处 《中国实用医刊》 2015年第14期19-20,共2页 Chinese Journal of Practical Medicine
关键词 度洛西汀 糖尿病 周围神经痛 Duloxetine Diabetes Peripheral neuropathie pain
  • 相关文献

参考文献5

二级参考文献32

  • 1于化梅,张玲,姜友昭,王海惠,陈兵.2型糖尿病周围神经病变的临床分析[J].第三军医大学学报,2003,25(13):1145-1145. 被引量:3
  • 2Ziegler D, Pritchett YL, Wang F, et al. Impact of disease character- istics on the eficacy of duloxetine in diabetic peripheral neuropathic pain[ J]. Diabetes Care,2007,30( 3 ) :664 - 669.
  • 3许樟荣,敬华,译.糖尿病足国际临床指南[M].北京:人民军医出版社,2003:20-22.
  • 4Gahimer J, Wemicke J, Yalcin 1, et al. A retrospective pooled anal- ysis of duloxetine safety in 23,983 subjects [ J ]. Curr Med Res Opin,2007,23( 1 ) :175 - 184.
  • 5Raskin J, Smith TR, W ong K, et al. Duloxetine versus routine care in the long - term management of diabetic peripheral neuropathic pain[ J]. J Palliat Med ,2006,9( 1 ) :29 -40.
  • 6Wang J, Liu X, Mullins CD. Treatment adherence and persistence with du- loxetine, venlafaxine XR,and escitalopram among patients with major de- pressive disorder and chronic pain-related diseases [J]. Curr Med ResOpin,2011 ;27(7) :1303-13.
  • 7Raskin J,Smith TR,Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain [J].J Palli- at Med,2006 ;9( 1 ) :29-40.
  • 8Wernieke JF, Raskin J, Rosen A, et al. Duloxetine in the long-term man- agement of diabetic peripheral neuropathie pain : an open-label, 52-week extension of a randomized controlled elinieal trial[J].Curr Therap Res,2006;65(5) : 283-304.
  • 9Wernicke JF,Wang F,Pritchett YL,et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabeticperipheral neuropathic pain [J].Pain Med, 2007 ; 8 ( 6 ) : 503-13.
  • 10蒋丙年.实用神经病学[M].2版.上海:上海科学技术出版社,1999:980.

共引文献27

同被引文献12

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部